Abstract
The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Pharmacokinetics of Biologic Agents
Volume: 9 Issue: 1
Author(s): Turhan Dost
Affiliation:
Keywords: Biologic agents, pharmacokinetic, TNF-α blocking agents, IL-1 receptor antagonist, anti-B cell antibody, T-cell activator, IL-6 inhibitor
Abstract: The deficiency of conventional drugs that are used in inflammatory rheumatic diseases are not able to prevent from progression of diseases have resulted in the development of new drugs, such as TUMOR Necrosis Factor-α (TNF-α) blocking agents, Interleukin-1 (IL-1) receptor antagonist and Anti-B cell (CD20) antibody. Biologic agents are a clear advancement in drug therapy. These newer agents have mechanisms of action targeted toward specific components of the immune system, which enable them to provide more reliable outcomes with fewer limiting side effects. They are administered subcutaneously and/or intravenously. The goal of the biologic treatment is to slow or block specific components of the immune system and halt tissue destruction.
Export Options
About this article
Cite this article as:
Dost Turhan, The Pharmacokinetics of Biologic Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711700
DOI https://dx.doi.org/10.2174/187152310790711700 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Normobaric Hyperoxia Preconditioning Induces Changes in the Brain Lipidome
Current Neurovascular Research Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Engineering Antibodies for Therapy
Current Pharmaceutical Biotechnology Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy
Current Cancer Drug Targets Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets Integrase Interactor 1 in Health and Disease
Current Protein & Peptide Science Synthesis and Biological Evaluation of a Novel Apogossypolone Derivative
Letters in Drug Design & Discovery Gene Expression Profile Classification: A Review
Current Bioinformatics Therapeutic Potential of Lymphoid Infiltrates in Breast Cancer
Current Medicinal Chemistry Dyspnea and Cough: A Rare Report of the Kimura Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Aptamers: Evolving to Find their Clinical Niche
Current Medicinal Chemistry Editorial: Looking Forward to Another Successful Year
Current Cancer Drug Targets